Gene Therapy Cell Culture Media Market to Reach USD 600.11 Billion by 2035

April 23, 2026 |

1 min read

Quick Facts

➔Gene therapy cell culture media industry poised to reach USD 237.66 billion by 2026.

➔Forecasted to grow to USD 600.11 billion by 2035.

➔Expected to maintain a CAGR of 10.84% from 2026 to 2035.

➔North America dominated the gene therapy cell culture media market revenue share of approximately 44% in 2025.

➔Asia Pacific is expected to grow at the fastest CAGR in the market during the forecast period.

➔By product/media type, the serum-free media segment dominated the market with a revenue share of approximately 46%.

➔By product/media type, the custom/optimized media (CDMO offerings) segment is expected to grow at the fastest CAGR in the market during the forecast period.

➔By application/process stage, the upstream viral vector production segment led the gene therapy cell culture media market with the largest revenue share of approximately 44% in 2025.

➔By application/process stage, the process development & optimization segment is expected to grow at the fastest CAGR in the market during the forecast period.

➔By cell type/target cell line, the HEK293/HEK293T segment held the highest market share of approximately 38% in 2025.

➔By cell type/target cell line, the primary T cells segment is expected to grow at the fastest CAGR in the market during the forecast period.

➔By formulation/format, the liquid ready-to-use media segment held the highest revenue shares of approximately 62% in 2025.

➔By formulation/format, the custom blends segment is expected to grow at the fastest CAGR in the market during the forecast period.

➔By end user, the pharmaceutical & biotechnology companies segment dominated the gene therapy cell culture media market with a major revenue share of approximately 50% in the market in 2025.

➔By end user, the CDMOs/viral vector CMOs segment is expected to grow at the fastest CAGR in the market during the forecast period.

Gene Therapy Cell Culture Media Market Size and Trends for 2026

The global gene therapy cell culture media market size was estimated at USD 214.42 billion in 2025 and is predicted to increase from USD 237.66 billion in 2026 to approximately USD 600.11 billion by 2035, expanding at a CAGR of 10.84% from 2026 to 2035.

The Complete Study is Now Available for Immediate Access | Download the Free Sample Pages of this Report @ https://www.towardshealthcare.com/download-sample/6089

The cell culture media are indispensable for cell growth and function due to the presence of necessary cell culture components and an ideal cell culture environment. The formulations vary depending on the need of cell culture conditions, including pH, osmotic pressure, temperature, etc. The different kinds of media used for cell and gene therapy are benchstable media, human plasma-like medium, media with GlutaMAX supplement, cell culture media for bioprocessing, media 199, Ham’s F-12 nutrient mixture, Ham’s F-10 nutrient mixture, and Iscove’s Modified Dulbecco’s Medium (IMDM).

Comprehensive Media Solutions and Services Offered by Sartorius AG

Sr. No.	Cell Therapy Media	HEK Media	Viral Vaccine Media	CHO Media	Classical Media
	Immune cell Media	HEK293 Media	MDCK Suspension Platform	CHO Cell Culture Media and Feeds	Classical Cell Culture Media
	Stem Cell Media	Recombinant Human Albumin	Vero Cell Media	CHO CLD Services	Cell Culture Lab Waters & Buffers
	Preclinical and GMP Growth Factors and Cytokines	Spent Media Analysis	Buffers	Spent Media Analysis	Cell Culture Reagents & Supplements
	Research Use Only Growth Factors and Cytokines	Custom Media and Buffers	Custom Media & Buffers	Custom Media & Buffers	Ultroser
	Cell Biopreservation Solutions	Transfection Reagents	Microcarriers	Buffers	Research Use Only (RUO) Growth Factors & Cytokines
	Recombinant Human Albumin	Plasmid Engineering & Sequencing Service	-	Transfection Reagents	NexaGel 3D Cell Culture Matrices
	Linkit AX Aliquoting System	Plasmid Manufacturing Service	-	Plasmid Engineering & Sequencing Service	-
	Spent Media Analysis	AAV Testing Services	-	Plasmid Manufacturing Service	-
	Non-Viral Delivery Solutions	Buffers	-	-	-
	Microcarriers	-	-	-	-

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

Market Overview: Expanding Scientific Innovations and Deep Research Expertise

The gene therapy cell culture media market is driven by the leading companies, such as Thermo Fisher Scientific Inc., which provide media for stem cell culture, organoid, spheroid, and 3D cell culture, neuronal cell culture, primary cell culture, cell therapy systems, protein expression media, serum-free media, and media for cytogenetic research. The products present in the cell culture media line contribute to the growth and maintenance of a wide range of mammalian cells and cell lines.

Become a valued research partner with us - https://www.towardshealthcare.com/schedule-meeting

Gene Therapy Cell Culture Media Market: Regional Analysis

North America led the market share by 44% in 2025, owing to biomanufacturing scale-up, government funding and incentives for research and development, and expanding clinical pipelines. The government programs boost clinical trials and harmonise global regulatory standards. The U.S. FDA aims to advance the rare disease therapeutics program through clinical trials. The FDA Rare Disease Innovation Hub is responsible for providing cross-agency expertise to address policy and scientific issues in the development of rare disease products.

For instance,

➔ In February 2026, Pfizer launched a cost savings program on TrumpRx to lower drug costs for millions of Americans. This program offers cost savings on over 30 brands related to women’s health, arthritis, migraine, rare diseases, and more.

U.S. Market Analysis

The gene therapy cell culture media market is gaining momentum in the U.S. due to the significant role of the U.S. government in positioning America as a global leader in pharmaceutical innovation. It enables patients to pay lower prices for their prescription medicines.

For instance,

➔ In April 2025, Novartis announced its initiatives to expand its U.S.-based manufacturing and advance its R&D footprint with a total investment of $23 billion over the next five years. These plans enabled Novartis to expand its R&D and manufacturing presence across the U.S. with 10 facilities.

Asia Pacific is expected to grow at the fastest rate in the market due to the expansion of biomanufacturing infrastructure, supportive government policies for biotechnology innovations, and the rising clinical trial activities. This region experiences the boom of gene and cell therapy manufacturing, and rapid growth through biotechnology investments in Japan, China, India, and South Korea. The investments in cell and gene therapies are made to advance R&D in oncology and regenerative medicine.

For instance,

➔ In March 2026, AstraZeneca announced its plans to establish cell therapy production and supply base in Shanghai, which positions this company as the first global leading biopharmaceutical company with end-to-end cell therapy capabilities in China. It has also signed a MoU with the Shanghai Municipal Science and Technology Commission and leading institutions in scientific research and financial sectors in the UK.

India Market Trends

The gene therapy cell culture media market in India is growing and expanding due to supportive government policies like the BioE3 policy and Biopharma SHAKTI, cost-effective manufacturing, and a shift to specialized media to meet international regulatory standards. India faces the growing challenges of cancer, which makes it rank second globally in cancer mortality. Research suggests that about 40% of patients relapse or resist chemotherapy and other standard treatments for aggressive B-cell malignancies like large B-cell lymphoma and acute lymphoblastic leukemia.

For instance,

In January 2026, Cipla partnered with ImmunoACT to expand access to the World’s first humanised CAR-T cell therapy named talicabtagene autoleucel (hashtag#NexCAR19) for patients in Africa. This collaboration aims to address critical unmet needs in oncology through affordability, innovation, and scientific excellence. Under this partnership, Cipla will commercialize India’s first CAR-T cell therapy in Morocco, the Republic of South Africa, and Algeria. Furthermore, NexCAR19 was honored among the top three innovations in India, in the presence of India’s Hon’ble Prime Minister, Shri Narendra Modi.

Get the latest insights on life science industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership

Gene Therapy Cell Culture Media Market: Segmentation Analysis

Product/Media Type Insights

Market Segment	2025 (%)
Serum-Free Media	46%
Custom/Optimized Media (CDMO offerings)	10%
Basal Media	15%
Xeno-Free Media	8%
Feed & Supplement Solutions	6%
Cryopreservation & Holding Media	6%
FreeStyle / Chemically Defined Suspension Media	9%

The serum-free media segment dominated the market by 46% in 2025, owing to the immense potential of this media to streamline and optimize CAR-T cell manufacturing workflows. It offers ways to overcome challenges associated with cost, complexity, and availability of CAR-T therapies to cancer patients. Researchers test and qualify all the components used in serum-based expansion media to ensure high levels of sterility and absence of impurities.

The custom/optimized media is expected to grow at the fastest rate in the gene therapy cell culture media market due to the use of custom media early in process development to achieve significant savings in time and resources. The customizable cell culture media are beneficial for therapeutic development and streamline early-stage discovery. Custom media services accelerate product timeline to market and provide flexibility and regulatory support.

Application/Process Stage Insights

The upstream viral vector production segment led the market in 2025, owing to the pivotal stages, like cell line selection, cell line expansion, and the production of viral vectors. The viral yield is impacted by the productivity and decision-making in upstream processing. The choice of media and transfection methods determines the productivity in upstream processing.

The process development & optimization segment is expected to grow at the fastest rate in the gene therapy cell culture media market due to the importance of process development in manufacturing a clinically and commercially viable therapeutic product. Researchers need to consider the best practices and identify manufacturing gaps during process development. Appropriate bioprocessing and development studies are conducted to produce a promising therapeutic product.

Cell Type/Target Cell Line Insights

Market Segment	2025 (%)
HEK293 / HEK293T	38%
Primary T Cells	10%
Stem Cells (iPSC / MSC)	15%
CHO (Biologics / Some Vector Workflows)	12%
Other Producer or Specialist Cell Lines (e.g., insect cells)	25%

The HEK293/HEK293T segment dominated the market share by 38% in 2025, owing to its role as a novel platform to produce viral vectors and recombinant proteins. It is the second most employed cell line used in the production of biopharmaceuticals and the conduct of academic research. The HEK293 cells have high transfection efficiency, which makes them a unique and ideal platform for expressing recombinant proteins.

The primary T cells segment is expected to grow at the fastest rate in the gene therapy cell culture media market due to the high preference of researchers for primary T cells for genetic engineering through viral vectors or non-viral methods. They present a more relevant physiological environment during R&D and quality control. Industries prefer them to test nutrient and metabolic profiling that impacts cell function.

Formulation/Format Insights

Market Segment	2025 (%)
Liquid Ready-to-Use Media	62%
Powder / Concentrate Media	10%
Kits (media + supplements + feeds)	10%
Custom Blends	18%

The liquid ready-to-use media segment dominated the market share by 62% in 2025, owing to the high preference for liquid media for bench-scale processes. It requires minimal preparation steps and is ready-to-use, which makes it an ideal solution for small-scale gene therapy development. It supports streamlined operations and consistent manufacturing processes.

The custom blends segment is expected to grow at the fastest rate in the gene therapy cell culture media market due to its core roles in maximizing viral vector yields and enabling seamless scale-up in industrial processes. They allow manufacturers to maintain regulatory compliance and protect therapeutic efficacy. They reduce the risk of viral contamination and ensure batch-to-batch consistency.

End User Insights

Market Segment	2025 (%)
Pharmaceutical & Biotechnology Companies	50%
CDMOs / Viral Vector CMOs	20%
Academic & Research Institutes	15%
Hospitals / Cell Therapy Treatment Centers	5%
Diagnostics / Lab Service Providers	10%

The pharmaceutical & biotechnology companies segment dominated the market share by 50% in 2025, owing to the globally leading innovations, scientific expertise, and transparency in customer relationships. The global biopharmaceutical companies have set their goals and are committed to delivering promising healthcare solutions. They focus on reducing industrial process timelines and producing cost-efficient products and services.

The CDMOs/viral vector CMOs segment is expected to grow at the fastest rate in the gene therapy cell culture media market due to the expansion of the leading contract manufacturing organizations and contract development manufacturing organizations, which provide services like viral vector production. They collaborate with the leading partners from pharmaceutical and biotechnology companies to offer deep expertise, technical consultation, bioinstrumentation, products, services, and technological innovations.

Access our comprehensive healthcare dashboard for detailed market insights, segment breakdowns, regional performance, and company profiles: https://www.towardshealthcare.com/access-dashboard

Gene Therapy Cell Culture Media Market Companies

• PromoCell

• CellGenix

• Thermo Fisher/Invitrogen

• Merck Millipore

• Corning Life Sciences

• HiMedia/Biological supply regional players

• WuXi AppTec

• VectorBuilder

• Irvine Scientific

• Sartorius

• Miltenyi Biotec

• Biological Industries

• Cytiva

• Takara Bio

• BioLife Solutions

• Charles River Laboratories

• Thermo Fisher Scientific

• Lonza

• Merck/MilliporeSigma

• FUJIFILM Irvine Scientific

Segments Covered in the Report

By Product/Media Type

• Basal Media

• DMEM/F12 variants (adherent HEK workflows)

• FreeStyle/chemically defined suspension media (HEK293 suspension)

• Serum-Free Media

• Formulated serum-free for adherent cells

• Serum-free for suspension cells

• Xeno-Free Media

• Human platelet lysate alternatives

• Fully defined xeno-free formulations

• Feed & Supplement Solutions

• Feed media (fed-batch for HEK/CHO)

• Transfection enhancers & boosters

• Cryopreservation & Holding Media

• CryoStor®-type freezing media

• HypoThermosol® and shipping media

• Custom/Optimized Media (CDMO offerings)

By Application/Process Stage

• Upstream Viral Vector Production

• AAV production (transient transfection or producer cell lines)

• Lentiviral/Retroviral production (transfection or stable producer lines)

• Cell Engineering & Expansion

• Primary T-cell expansion for CAR-T/NK cell therapies

• Stem cell expansion (iPSC, MSC)

• Transfection & Transduction

• Transient transfection media + enhancers

• Stable cell line maintenance media

• Process Development & Optimization

• Media optimization services for scale-up and regulatory compliance.

By Cell Type/Target Cell Line 

• HEK293/HEK293T

• Adherent HEK media subvariants

• Suspension HEK optimized media

• CHO (Biologics/some vector workflows)

• Primary T Cells

• T-cell activation & expansion media

• Cytokine-supplemented feeds (IL-2, IL-7/15 supports)

• Stem Cells (iPSC/MSC)

• Other producer or specialist cell lines (e.g., producer lines, insect cells for certain vectors)

By Formulation/Format

• Liquid Ready-to-Use Media

• Powder/Concentrate Media (cost/storage advantages)

• Kits (media + supplements + feeds)

• Custom Blends

By End User

• Pharmaceutical & Biotechnology Companies

• In-house vector production & cell therapy pipelines.

• CDMOs/Viral Vector CMOs (Fastest Growing)

• Outsourced large-scale AAV/lenti production requiring tailored GMP media.

• Academic & Research Institutes

• Hospitals/Cell Therapy Treatment Centers

• Diagnostics/Lab Service Providers

By Region

• North America

• Asia Pacific

• Europe

• Latin America

• Middle East and Africa (MEA)

Immediate Delivery Available | Buy This Research Report Now @ https://www.towardshealthcare.com/checkout/6089

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

Europe Region: +44 778 256 0738

North America Region: +1 8044 4193 44

APAC Region: +91 9356 9282 04

Web: https://www.towardshealthcare.com

Our Trusted Data Partners

Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest

Browse More Insights of Towards Healthcare:

The gene therapy platform market size was valued at US$ 2.25 billion in 2025 and is projected to grow to 2.59 billion in 2026. Forecasts suggest it will reach approximately US$ 9.29 billion by 2035, registering a CAGR of 15.23% during the period.

The worldwide gene therapy for sickle cell disease market is experiencing significant expansion, with projections indicating a revenue increase reaching several hundred million dollars by the end of the forecast period, spanning 2025 to 2034.

The global gene therapy market size is calculated at USD 9.5 in 2024, grew to USD 11.4 billion in 2025, and is projected to reach around USD 58.87 billion by 2034. The market is expanding at a CAGR of 20% between 2025 and 2034.

The gene therapy clinical trials market size was valued at US$ 1.36 billion in 2025 and is projected to grow to 1.49 billion in 2026. Forecasts suggest it will reach approximately US$ 3.29 billion by 2035, registering a CAGR of 9.24% during the period.

The viral vector gene therapy market size reached US$ 13.14 billion in 2024 and is anticipate to increase to US$ 14.62 billion in 2025. By 2034, the market is forecasted to achieve a value of around US$ 38.39 billion, growing at a CAGR of 11.23%.

The AAV gene therapy market size was estimated at US$ 3.85 billion in 2025, projected to increase to US$ 5.4 billion in 2026 and reach US$ 112.24 billion by 2035, showing a healthy CAGR of 40.1% across the forecast years.

The U.S. cell and gene therapy CRO market size was estimated at USD 2.33 billion in 2025 and is predicted to increase from USD 2.56 billion in 2026 to approximately USD 6.02 billion by 2035, expanding at a CAGR of 9.95% from 2026 to 2035.

The AAV manufacturing service market size touched US$ 1.44 billion in 2025, with expectations of climbing to US$ 1.66 billion in 2026 and hitting US$ 6.25 billion by 2035, driven by a CAGR of 15.84% over the forecast period.

The global cell & gene therapy logistics market size is estimated at US$ 6.41 billion in 2025, is projected to grow to US$ 7.76 billion in 2026, and is expected to reach around US$ 43.14 billion by 2035. The market is projected to expand at a CAGR of 21% between 2026 and 2035.

The global cell and gene therapy CRO market size is estimated at US$ 4.90 billion in 2024, is projected to grow to US$ 5.39 billion in 2025, and is expected to reach around US$ 12.59 billion by 2034. The market is projected to expand at a CAGR of 9.9% between 2025 and 2034.